Cardiff Oncology Management
Management criteria checks 4/4
Cardiff Oncology's CEO is Mark Erlander, appointed in May 2020, has a tenure of 4.58 years. total yearly compensation is $1.55M, comprised of 38.4% salary and 61.6% bonuses, including company stock and options. directly owns 0.048% of the company’s shares, worth $95.97K. The average tenure of the management team and the board of directors is 2.9 years and 10.3 years respectively.
Key information
Mark Erlander
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 38.4% |
| CEO tenure | 4.6yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2.9yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Dec 12Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$2m | US$594k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$39m |
| Dec 31 2022 | US$2m | US$571k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$4m | US$533k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$1m | US$445k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$853k | US$399k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$909k | US$387k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$20m |
| Dec 31 2017 | US$1m | US$374k | -US$25m |
Compensation vs Market: Mark's total compensation ($USD1.55M) is about average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Erlander (64 yo)
4.6yrs
Tenure
US$1,547,772
Compensation
Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.6yrs | US$1.55m | 0.048% $ 96.0k | |
| Chief Financial Officer | 3.4yrs | US$917.72k | 0.13% $ 265.4k | |
| Chief Medical Officer | 1.8yrs | US$1.26m | 0% $ 0 | |
| Chief Scientific Officer | 2.9yrs | US$4.17m | 0% $ 0 | |
| VP of Finance & Administration | 9.4yrs | no data | no data | |
| Senior Vice President of Finance | 1.9yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
61.5yo
Average Age
Experienced Management: CRDF's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.5yrs | US$1.55m | 0.048% $ 96.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.7yrs | US$114.43k | 2.07% $ 4.2m | |
| Member of Scientific Advisory Board | 10.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 12.1yrs | US$35.85k | no data | |
| Independent Chairman of the Board | 10.8yrs | US$154.43k | 0.061% $ 121.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 14.7yrs | no data | no data | |
| Independent Director | 4.7yrs | US$116.43k | 0.22% $ 446.0k | |
| Member of Scientific Advisory Board | 10.3yrs | no data | no data | |
| Independent Director | 3.5yrs | US$110.43k | 0.039% $ 78.4k | |
| Member of Scientific Advisory Board | 14.7yrs | no data | no data |
10.3yrs
Average Tenure
72yo
Average Age
Experienced Board: CRDF's board of directors are seasoned and experienced ( 10.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 07:17 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cardiff Oncology, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Sung Ji Nam | Avondale Partners |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |